Aliases & Classifications for Raynaud Phenomenon

MalaCards integrated aliases for Raynaud Phenomenon:

Name: Raynaud Phenomenon 25 73
Raynaud Disease 25 73
Raynaud's 25 63
Secondary Raynaud's Phenomenon 73
Raynaud's Phenomenon 25
Raynauds Phenomenon 55
Raynaud's Syndrome 25
Raynaud's Disease 25
Raynauds Syndrome 55
Raynaud Syndrome 37

Classifications:



External Ids:

KEGG 37 H01620
ICD10 33 I73.0

Summaries for Raynaud Phenomenon

PubMed Health : 63 About raynaud's: Raynaud's is a rare disorder that affects the arteries. Arteries are blood vessels that carry blood from your heart to different parts of your body.Raynaud's sometimes is called a disease, syndrome, or phenomenon. The disorder is marked by brief episodes of vasospasm (VA-so-spazm), which is a narrowing of the blood vessels.Vasospasm of the arteries reduces blood flow to the fingers and toes. In people who have Raynaud's, the disorder usually affects the fingers. In about 40 percent of people who have Raynaud's, it affects the toes. Rarely, the disorder affects the nose, ears, nipples, and lips.

MalaCards based summary : Raynaud Phenomenon, also known as raynaud disease, is related to raynaud disease and antiphospholipid syndrome, and has symptoms including abdominal pain, angina pectoris and chest pain. An important gene associated with Raynaud Phenomenon is EDN1 (Endothelin 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Vascular smooth muscle contraction. The drugs Cilostazol and Vasodilator Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, heart and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Genetics Home Reference : 25 Raynaud phenomenon is a condition in which the body's normal response to cold or emotional stress is exaggerated, resulting in abnormal spasms (vasospasms) in small blood vessels called arterioles. The disorder mainly affects the fingers but can also involve the ears, nose, nipples, knees, or toes. The vasospasms reduce blood circulation, leading to discomfort and skin color changes.

Wikipedia : 76 Raynaud syndrome, also known as Raynaud\'s phenomenon, is a medical condition in which spasm of arteries... more...

Related Diseases for Raynaud Phenomenon

Diseases related to Raynaud Phenomenon via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Related Disease Score Top Affiliating Genes
1 raynaud disease 32.5 EDN1 VWF
2 antiphospholipid syndrome 29.1 APOH THBD
3 pulmonary hypertension 28.5 EDN1 PDE5A THBD VWF
4 crest syndrome 11.6
5 scleroderma, familial progressive 11.5
6 antisynthetase syndrome 11.1
7 undifferentiated connective tissue disease 11.1
8 angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps 11.1
9 reynolds syndrome 11.1
10 moyamoya disease 6 with achalasia 11.1
11 angina pectoris 10.5 EDN1 VWF
12 unilateral absence of a pulmonary artery 10.5 THBD VWF
13 spotted fever 10.4 THBD VWF
14 hepatopulmonary syndrome 10.4 EDN1 VWF
15 limb ischemia 10.3 EDN1 VWF
16 aortic coarctation 10.3 AGTR1 EDN1
17 malignant hypertension 10.3 AGTR1 EDN1
18 blood coagulation disease 10.3 THBD VWF
19 myocardial stunning 10.3 AGTR1 EDN1
20 renal hypertension 10.2 AGTR1 EDN1
21 hemorrhagic disease 10.2 THBD VWF
22 renovascular hypertension 10.2 AGTR1 EDN1
23 acute mountain sickness 10.2 AGTR1 EDN1
24 takayasu arteritis 10.1 THBD VWF
25 sexual disorder 10.1 EDN1 PDE5A
26 persistent fetal circulation syndrome 10.1 EDN1 PDE5A
27 hemolytic-uremic syndrome 10.1 THBD VWF
28 peripheral vascular disease 10.0 THBD VWF
29 eisenmenger syndrome 10.0 EDN1 THBD VWF
30 diabetic angiopathy 10.0 EDN1 THBD VWF
31 impotence 10.0 EDN1 PDE5A
32 intracranial thrombosis 10.0 APOH VWF
33 factor xii deficiency 9.9 APOH VWF
34 optic nerve disease 9.9 EDN1 PDE5A
35 eclampsia 9.9 EDN1 THBD
36 portal hypertension 9.9 AGTR1 EDN1 VWF
37 arteries, anomalies of 9.9 AGTR1 EDN1 VWF
38 acute myocardial infarction 9.9 AGTR1 EDN1 VWF
39 prothrombin deficiency 9.9 APOH THBD
40 carotid artery occlusion 9.9 APOH THBD
41 intermittent claudication 9.9 APOH VWF
42 placental abruption 9.8 APOH THBD
43 multiple sclerosis 9.7
44 connective tissue disease 9.7
45 erythermalgia, primary 9.7
46 neuropathy 9.7
47 pulmonary hypertension, primary, 1 9.7
48 paresthesia 9.7
49 lung cancer 9.7
50 multicentric reticulohistiocytosis 9.7

Comorbidity relations with Raynaud Phenomenon via Phenotypic Disease Network (PDN):


Deficiency Anemia Esophagitis
Hypertension, Essential Hypothyroidism
Ischemic Heart Disease Peripheral Vascular Disease
Systemic Lupus Erythematosus Systemic Scleroderma

Graphical network of the top 20 diseases related to Raynaud Phenomenon:



Diseases related to Raynaud Phenomenon

Symptoms & Phenotypes for Raynaud Phenomenon

UMLS symptoms related to Raynaud Phenomenon:


abdominal pain, angina pectoris, chest pain, cold intolerance, constipation, coughing, diarrhea, dyspepsia, edema, fatigue, fever, halitosis, headache, heartburn, icterus, nausea and vomiting, pain, pelvic pain, pruritus, sciatica, syncope, chronic pain, vertigo/dizziness, gastrointestinal gas, symptoms, joint or joint related complaint

MGI Mouse Phenotypes related to Raynaud Phenomenon:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.55 ADRA2C AGTR1 EDN1 THBD VWF
2 homeostasis/metabolism MP:0005376 9.43 ADRA2C AGTR1 APOH EDN1 THBD VWF
3 mortality/aging MP:0010768 9.1 ADRA2C AGTR1 APOH EDN1 THBD VWF

Drugs & Therapeutics for Raynaud Phenomenon

PubMedHealth treatment related to Raynaud Phenomenon: 63

Primary Raynaud's (Raynaud's disease) and secondary Raynaud's (Raynaud's phenomenon) have no cure. However, treatments can reduce the number and severity of Raynaud's attacks. Treatments include lifestyle changes, medicines, and, rarely, surgery.Most people who have primary Raynaud's can manage the condition with lifestyle changes. People who have secondary Raynaud's may need medicines in addition to lifestyle changes. Rarely, they may need surgery or shots.If you have Raynaud's and develop sores on your fingers, toes, or other parts of your body, see your doctor right away. Timely treatment can help prevent permanent damage to these areas.

Drugs for Raynaud Phenomenon (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
2 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
3 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
4 Fibrinolytic Agents Phase 4
5 Respiratory System Agents Phase 4
6 Neuroprotective Agents Phase 4,Early Phase 1
7 Anti-Asthmatic Agents Phase 4
8 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
9 Phosphodiesterase 3 Inhibitors Phase 4
10 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
11 Protective Agents Phase 4,Early Phase 1
12 Autonomic Agents Phase 4,Early Phase 1
13 Bronchodilator Agents Phase 4
14
Nitroglycerin Approved, Investigational Phase 3,Phase 2,Phase 1 55-63-0 4510
15
Amlodipine Approved Phase 2, Phase 3 88150-42-9 2162
16
Nifedipine Approved Phase 3,Early Phase 1 21829-25-4 4485
17
Acetylcholine Approved Phase 3,Phase 2,Not Applicable 51-84-3 187
18
Iloprost Approved, Investigational Phase 3,Phase 2 78919-13-8 6443959
19
Tadalafil Approved, Investigational Phase 3,Phase 2,Not Applicable 171596-29-5 110635
20
Udenafil Approved, Investigational Phase 2, Phase 3 268203-93-6 6918523
21
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 3,Early Phase 1 77-92-9 311
22
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
23 Fasudil Investigational Phase 3 103745-39-7
24 Antihypertensive Agents Phase 2, Phase 3,Phase 1,Not Applicable,Early Phase 1
25 insulin Phase 3
26 Sildenafil Citrate Phase 2, Phase 3,Phase 3,Early Phase 1 171599-83-0
27 calcium channel blockers Phase 2, Phase 3,Phase 3,Early Phase 1
28 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine Phase 3
29 abobotulinumtoxinA Phase 3,Phase 2,Not Applicable
30 Chelating Agents Phase 3
31 Cholinergic Agents Phase 3,Phase 2,Not Applicable
32 Neuromuscular Agents Phase 3,Phase 2,Not Applicable
33 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
34 Tocolytic Agents Phase 3,Early Phase 1
35 onabotulinumtoxinA Phase 3,Phase 2,Not Applicable
36 Vardenafil Dihydrochloride Phase 2, Phase 3
37 Pharmaceutical Solutions Phase 3,Phase 2,Not Applicable,Early Phase 1
38 Phosphodiesterase 5 Inhibitors Phase 2, Phase 3,Phase 3,Not Applicable,Early Phase 1
39 Anticoagulants Phase 3
40 Insulin, Globin Zinc Phase 3
41 Protein Kinase Inhibitors Phase 3,Phase 1,Phase 2
42 Botulinum Toxins, Type A Phase 3,Phase 2,Not Applicable
43 Botulinum Toxins Phase 3,Phase 2,Not Applicable
44 Calcium, Dietary Phase 2, Phase 3,Phase 3,Early Phase 1,Not Applicable
45 Citrate Nutraceutical Phase 2, Phase 3,Phase 3,Early Phase 1
46
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
47
Alprostadil Approved, Investigational Phase 2,Not Applicable 745-65-3 149351 5280723
48
Treprostinil Approved, Investigational Phase 2,Phase 1,Early Phase 1 81846-19-7 54786 6918140
49 Selexipag Approved Phase 2 475086-01-2
50
Methocarbamol Approved, Vet_approved Phase 2 532-03-6 4107

Interventional clinical trials:

(show top 50) (show all 81)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048763 Phase 4 Pletal
2 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4 Pletal
3 Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Scleroderma Patients Enrolling by invitation NCT03558854 Phase 4 Acetylsalicylic acid;Placebo oral capsule
4 Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms Unknown status NCT00934427 Phase 3 0.9% nitroglycerin in TAM cream;vehicle cream
5 A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon Unknown status NCT00577304 Phase 3 Nitroglycerin;Topical AmphiMatrix
6 "As Required" Oral Sildenafil in Raynaud's Phenomenon Completed NCT02050360 Phase 2, Phase 3 Sildenafil 40 mg;Sildenafil 80 mg;Placebo
7 Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon Completed NCT01280266 Phase 2, Phase 3 Udenafil or Amlodipine
8 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT01117298 Phase 3 Tadalafil;Placebo
9 Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome Completed NCT01291199 Phase 2, Phase 3 vardenafil;Placebo
10 A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon Completed NCT00498615 Phase 3 Fasudil
11 St. John's Wort in the Treatment of Raynaud's Phenomenon Completed NCT00351117 Phase 3 St. John's Wort;Lactose
12 Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon Completed NCT00266669 Phase 3 Topical organogel with nitroglycerin
13 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3 Onabotulinumtoxin A;sterile saline solution
14 Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT00626665 Phase 3 Tadalafil
15 Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon Completed NCT00419419 Phase 3 Topical AmphiMatrix with nitroglycerin (MQX-503)
16 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT00004786 Phase 3 iloprost
17 Lab Study of MQX-503 in Treatment of Raynaud's Completed NCT00253331 Phase 2, Phase 3 topical organogel with nitroglycerin
18 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
19 A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Completed NCT01553981 Phase 3 Tadalafil;Placebo
20 Raynaud's Treatment Study (RTS) Completed NCT00000530 Phase 3 nifedipine
21 Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY Completed NCT01295736 Phase 3 Sildenafil;placebo
22 A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis Completed NCT01532869 Phase 3 Placebo;tocilizumab [RoActemra/Actemra];tocilizumab [RoActemra/Actemra]
23 Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon Unknown status NCT02356809 Phase 1, Phase 2 Neovasculgen
24 Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis Unknown status NCT02558543 Phase 2 Stromal Vascular fraction;Ringer lactate
25 Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT02260557 Phase 2 Selexipag;Placebo
26 Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT02228850 Phase 2 Alprostadil
27 Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon Completed NCT02688270 Phase 2 Vascana (0.9% nitroglycerin cream);Vehicle (placebo)
28 Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator Completed NCT01926847 Phase 2 Riociguat (Adempas, BAY63-2521);Placebo
29 Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon Completed NCT00251238 Phase 2 Ginkgo biloba extract EGb 761
30 Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon Completed NCT00480753 Phase 2 Nitroglycerin
31 PF-00489791 For The Treatment Of Raynaud's Completed NCT01090492 Phase 2 PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791
32 Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon Completed NCT00378521 Phase 2 MQX-503
33 Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction Completed NCT00707187 Phase 2 Cialis
34 Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine Completed NCT00775463 Phase 2 treprostinil diethanolamine;placebo
35 Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis Completed NCT00004380 Phase 2 relaxin
36 Imatinib in Systemic Sclerosis Completed NCT00506831 Phase 1, Phase 2 Imatinib mesylate
37 Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children Completed NCT00502593 Phase 2
38 CSL Behring Sclero XIII Recruiting NCT02551042 Phase 2 Fibrogammin®P, coagulation factor XIII concentrate (Human);0.9% sodium chloride
39 Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma Recruiting NCT02370784 Phase 2 atorvastatin;Placebo
40 Brentuximab Vedotin for Systemic Sclerosis Recruiting NCT03222492 Phase 1, Phase 2
41 A Two-Part Study of BOTOX® Therapy for Ischemic Digits Active, not recruiting NCT01309802 Phase 2 onabotulinum toxin type-A
42 Riociguat in Scleroderma Associated Digital Ulcers Active, not recruiting NCT02915835 Phase 2 Riociguat;Placebo
43 Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) Active, not recruiting NCT01086540 Phase 2
44 Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) Active, not recruiting NCT02290613 Phase 2 Ambrisentan;Placebo
45 SCLERoderma et Adipose-DErived Stroma Cells Not yet recruiting NCT02866552 Phase 2 Stromal Vascular fraction;Ringer lactate
46 Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon Terminated NCT01315899 Phase 2 ORM-12471 30mg;ORM-12471;placebo
47 Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis Terminated NCT00622687 Phase 2 iloprost;iloprost low dose;iloprost therapy up to 2 ng/kg x min
48 Open-Label Study of Oral Treprostinil in Digital Ulcers Terminated NCT00848107 Phase 2 treprostinil diethanolamine
49 Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon Completed NCT00700518 Phase 1 placebo cream;Glyceryl Trinitrate;Glyceryl Trinitrate;Glyceryl Trinitrate;Glyceryl Trinitrate
50 MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic Comparison Completed NCT00841594 Phase 1 nitroglycerin 0.9 % (MXQ-503);Nitroglycerin ointment 2%, USP

Search NIH Clinical Center for Raynaud Phenomenon

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Raynaud Phenomenon

Anatomical Context for Raynaud Phenomenon

MalaCards organs/tissues related to Raynaud Phenomenon:

41
Skin, Heart, Endothelial, Lung, Bone Marrow, Bone

Publications for Raynaud Phenomenon

Articles related to Raynaud Phenomenon:

(show all 32)
# Title Authors Year
1
Ischaemic ulcers on the toes secondary to Raynaud phenomenon in a patient with systemic sclerosis successfully treated with botulinum toxin. ( 29274125 )
2018
2
Impairment of microcirculation and vascular responsiveness in adolescents with primary Raynaud phenomenon. ( 29566759 )
2018
3
The Frisbee maneuver: A novel method to abort acute attacks of the Raynaud phenomenon. ( 29017842 )
2018
4
Nifedipine cream versus sildenafil cream for patients with secondary Raynaud phenomenon: A randomized, double-blind, controlled pilot study. ( 29241781 )
2018
5
Antiphosphatidylserine/prothrombin (aPS/PT) antibodies are associated with Raynaud phenomenon and migraine in primary thrombotic antiphospholipid syndrome. ( 29338587 )
2018
6
Treating Raynaud phenomenon: Beyond staying warm. ( 28985172 )
2017
7
Follow-Up of Treatment Response With Dynamic Doppler Ultrasound in Raynaud Phenomenon. ( 28981361 )
2017
8
Popliteal artery entrapment syndrome presenting as Raynaud phenomenon. ( 28633610 )
2017
9
Finger pad tophi in a patient with Raynaud phenomenon. ( 28180145 )
2017
10
Unexpected drug-induced Raynaud phenomenon: Analysis from the French national pharmacovigilance database. ( 28336160 )
2017
11
Relation of Nailfold Capillaries and Autoantibodies to Mortality in Patients With Raynaud Phenomenon. ( 26733605 )
2016
12
Raynaud phenomenon causing lingual pallor and dysarthria. ( 27114484 )
2016
13
Iatrogenic Thenar Eminence Atrophy After Botox A Injection for Secondary Raynaud Phenomenon. ( 27660946 )
2016
14
Aberrant immune response with consequent vascular and connective tissue remodeling - causal to scleroderma and associated syndromes such as Raynaud phenomenon and other fibrosing syndromes? ( 27548652 )
2016
15
Nailfold Capillary Patterns in a Patient With Multicentric Reticulohistiocytosis and Raynaud Phenomenon. ( 27219314 )
2016
16
HTR1B gene variants associate with the susceptibility of Raynauds' phenomenon in workers exposed hand-arm vibration. ( 26639766 )
2016
17
Raynaud Phenomenon With Severe Ulcers Associated With Cryoglobulins in an HIV+ but HCV Negative Patient. ( 27433994 )
2016
18
A case report of the beneficial effects of botulinum toxin type A on Raynaud phenomenon in a patient with lung cancer. ( 27749585 )
2016
19
Abnormal Bone Marrow Signal Intensity in the Phalanges of the Foot as a Manifestation of Raynaud Phenomenon: A Report of Six Patients. ( 27575610 )
2016
20
Neonatal BehAset's disease with Raynaud phenomenon. ( 27834783 )
2016
21
Interferons beta have vasoconstrictive and procoagulant effects: A woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis. ( 24321162 )
2013
22
Prevalence of migraine and Raynaud phenomenon in women with apical ballooning syndrome (Takotsubo or stress cardiomyopathy). ( 23415512 )
2013
23
Telangiectases of the distal lower extremities associated with paresthesia and Raynaud phenomenon. ( 23324765 )
2013
24
Peripheral phenomena in a woman with calcinosis, raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia (CREST) syndrome-associated pulmonary hypertension. ( 22392867 )
2012
25
PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials. ( 22121375 )
2011
26
Primary Raynaud phenomenon and small-fiber neuropathy: is there a connection? A pilot neurophysiologic study. ( 20035332 )
2011
27
Bosentan treatment for Raynauds phenomenon and skin fibrosis in patients with Systemic Sclerosis and pulmonary arterial hypertension: an open-label, observational, retrospective study. ( 21244767 )
2010
28
Acrocyanosis from phenazopyridine-induced sulfhemoglobinemia mistaken for Raynaud phenomenon. ( 19300288 )
2009
29
Transcriptional activity of genes coding transforming growth factor beta-1 and its receptors in patients with systemic sclerosis and Raynaud phenomenon. ( 19299112 )
2009
30
Paraneoplastic Raynaud phenomenon with digital necrosis associated with hyperhomocysteinemia and antiphospholipid antibodies. ( 17938361 )
2007
31
The prognostic value of nailfold capillary changes for the development of connective tissue disease in children and adolescents with primary raynaud phenomenon: a follow-up study of 250 patients. ( 17014637 )
2006
32
[Raynaud phenomenon in dermatology. Part 1: Pathophysiology and diagnostic approach]. ( 16902805 )
2006

Variations for Raynaud Phenomenon

Expression for Raynaud Phenomenon

Search GEO for disease gene expression data for Raynaud Phenomenon.

Pathways for Raynaud Phenomenon

GO Terms for Raynaud Phenomenon

Cellular components related to Raynaud Phenomenon according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Weibel-Palade body GO:0033093 8.62 EDN1 VWF

Biological processes related to Raynaud Phenomenon according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 female pregnancy GO:0007565 9.51 ADRA2C THBD
2 positive regulation of MAP kinase activity GO:0043406 9.49 EDN1 PDE5A
3 calcium-mediated signaling GO:0019722 9.48 AGTR1 EDN1
4 hemostasis GO:0007599 9.46 THBD VWF
5 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway GO:0051482 9.43 AGTR1 EDN1
6 regulation of sensory perception of pain GO:0051930 9.4 ADRA2C EDN1
7 positive regulation of cardiac muscle hypertrophy GO:0010613 9.37 EDN1 PDE5A
8 blood coagulation, intrinsic pathway GO:0007597 9.32 APOH VWF
9 negative regulation of fibrinolysis GO:0051918 9.26 APOH THBD
10 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.16 APOH EDN1
11 regulation of vasoconstriction GO:0019229 9.13 ADRA2C AGTR1 EDN1
12 negative regulation of blood coagulation GO:0030195 8.8 APOH EDN1 THBD

Sources for Raynaud Phenomenon

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....